VA's McKesson Pharmaceutical Prime Vendor contract awarded $609M in FY2022, highlighting significant drug procurement needs

Contract Overview

Contract Amount: $609,005,032 ($609.0M)

Contractor: Mckesson Corporation

Awarding Agency: Department of Veterans Affairs

Start Date: 2021-12-01

End Date: 2021-12-31

Contract Duration: 30 days

Daily Burn Rate: $20.3M/day

Competition Type: FULL AND OPEN COMPETITION

Pricing Type: FIRM FIXED PRICE

Sector: Healthcare

Official Description: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2022 DECEMBER

Place of Performance

Location: IRVING, DALLAS County, TEXAS, 75039

State: Texas Government Spending

Plain-Language Summary

Department of Veterans Affairs obligated $609.0 million to MCKESSON CORPORATION for work described as: EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2022 DECEMBER Key points: 1. The contract demonstrates substantial government reliance on a single vendor for pharmaceutical supplies. 2. Pricing and value for money are critical considerations given the large contract value. 3. Competition dynamics for this essential service warrant close examination to ensure optimal taxpayer value. 4. Performance metrics and delivery reliability are key indicators of contractor effectiveness. 5. This contract positions McKesson as a central player in the federal pharmaceutical supply chain. 6. The fixed-price nature of the award provides cost certainty but requires careful monitoring of market fluctuations.

Value Assessment

Rating: good

The VA's Pharmaceutical Prime Vendor (PPV) program, with McKesson Corporation as a key awardee, represents a significant portion of the department's pharmaceutical spending. While specific per-unit cost data is not provided in this summary, the overall contract value of over $609 million in FY2022 suggests a large volume of pharmaceutical products procured. Benchmarking against similar large-scale prime vendor contracts across federal agencies would be necessary for a comprehensive value-for-money assessment. However, the existence of a prime vendor model generally aims to streamline procurement and achieve economies of scale, which can be indicative of good value.

Cost Per Unit: N/A

Competition Analysis

Competition Level: full-and-open

This contract was awarded under full and open competition, indicating that multiple qualified vendors had the opportunity to bid. The specific number of bidders is not detailed, but the 'full and open' designation suggests a competitive process designed to solicit the best offers. This level of competition is generally favorable for price discovery and ensuring that the government receives competitive pricing for essential goods and services.

Taxpayer Impact: Full and open competition for such a large and critical contract helps ensure that taxpayer dollars are used efficiently by driving down prices through a robust bidding process.

Public Impact

Veterans across the United States benefit from timely access to a wide range of pharmaceuticals through this contract. The contract ensures the availability of essential medications for the Department of Veterans Affairs healthcare system. Geographic impact is nationwide, supporting VA facilities and healthcare providers in all states. Workforce implications include the logistics and distribution network managed by McKesson to fulfill VA orders.

Waste & Efficiency Indicators

Waste Risk Score: 50 / 10

Warning Flags

Potential for over-reliance on a single vendor for critical pharmaceutical supplies.
Risk of price increases if market conditions shift significantly and are not adequately captured in the fixed-price agreement.
Dependence on McKesson's supply chain integrity and distribution network.

Positive Signals

Awarded through full and open competition, suggesting competitive pricing.
Fixed-price contract provides cost certainty for the VA.
Prime vendor model is designed for efficiency and streamlined procurement of pharmaceuticals.

Sector Analysis

The pharmaceutical manufacturing and distribution sector is a critical component of the healthcare industry. Federal agencies, particularly the Department of Defense and the Department of Veterans Affairs, are significant purchasers of pharmaceuticals. Prime vendor contracts, like this one with McKesson, are a common contracting vehicle used to ensure a steady and efficient supply of medications. The total federal spending on pharmaceuticals is substantial, and contracts of this nature represent a key part of that expenditure, aiming to leverage economies of scale and streamline complex supply chains.

Small Business Impact

While this contract is with a large prime vendor, McKesson Corporation, the implications for small businesses are indirect. Prime vendors often utilize subcontracting networks, which may include small businesses for specialized logistics, distribution, or other support services. However, without specific subcontracting plans or set-aside information, the direct impact on small businesses is not fully discernible from this award alone. The focus here is on the prime vendor's ability to manage the overall supply chain efficiently.

Oversight & Accountability

The Department of Veterans Affairs is responsible for the oversight of this contract, ensuring compliance with terms and conditions, performance standards, and delivery schedules. Accountability is maintained through performance monitoring and reporting mechanisms inherent in the contract. Transparency is generally facilitated through contract award databases and public reporting, although detailed operational data may be proprietary. The VA's Office of Inspector General may conduct audits or investigations related to pharmaceutical procurement and distribution.

Related Government Programs

Department of Defense Pharmaceutical Prime Vendor Program
Federal Supply Schedule (FSS) for Pharmaceuticals
National Acquisition Center (NAC) Contracts
VA Medical/Surgical Prime Vendor Program

Risk Flags

High contract value requires diligent oversight.
Dependence on a single prime vendor for critical supplies.
Need for ongoing price benchmarking to ensure value.

Frequently Asked Questions

What is this federal contract paying for?

Department of Veterans Affairs awarded $609.0 million to MCKESSON CORPORATION. EXPRESS REPORT: PHARMACEUTICAL PRIME VENDOR (PPV)FY2022 DECEMBER

Who is the contractor on this award?

The obligated recipient is MCKESSON CORPORATION.

Which agency awarded this contract?

Awarding agency: Department of Veterans Affairs (Department of Veterans Affairs).

What is the total obligated amount?

The obligated amount is $609.0 million.

What is the period of performance?

Start: 2021-12-01. End: 2021-12-31.

What is McKesson Corporation's track record with the Department of Veterans Affairs for pharmaceutical prime vendor services?

McKesson Corporation has a long-standing relationship with the Department of Veterans Affairs (VA) as a prime vendor for pharmaceuticals. They have consistently been a major awardee of these large-scale contracts, responsible for distributing a vast array of medications to VA medical centers and clinics nationwide. Their track record includes managing complex logistics, ensuring timely delivery, and maintaining a broad formulary of drugs. While specific performance scores or past issues are not detailed here, their continued success in winning these competitive contracts suggests a generally positive performance history and a strong understanding of the VA's requirements and operational environment. The scale of their involvement indicates a high level of trust and capability in fulfilling the VA's critical pharmaceutical needs.

How does the $609 million FY2022 award compare to previous years for this specific contract or similar VA pharmaceutical prime vendor contracts?

The $609 million figure for FY2022 represents the spending under this specific award for McKesson Corporation. To provide a comparative context, one would need to examine historical spending data for this particular contract vehicle or for the VA's overall Pharmaceutical Prime Vendor (PPV) program. Typically, federal spending on essential services like pharmaceuticals can fluctuate year-over-year due to changes in healthcare needs, drug pricing, formulary adjustments, and the number or size of active contracts. If this represents a significant increase or decrease, it could signal shifts in VA's procurement strategy, changes in drug utilization patterns among veterans, or evolving market dynamics. Without historical data points, it's challenging to definitively state whether this amount is higher or lower than previous periods, but it underscores the substantial and ongoing investment the VA makes in pharmaceutical procurement.

What are the primary risks associated with a sole-source or limited-competition award for essential pharmaceutical supplies?

While this contract was awarded under full and open competition, the question addresses risks associated with limited competition. A sole-source or limited-competition award for essential pharmaceutical supplies carries several significant risks. Firstly, it can lead to higher prices due to a lack of competitive pressure, potentially resulting in less value for taxpayer money. Secondly, it increases the government's dependence on a single or limited number of suppliers, making the supply chain more vulnerable to disruptions caused by the contractor's operational issues, financial instability, or geopolitical events. Thirdly, reduced competition can stifle innovation and may lead to complacency in service quality or efficiency. For critical items like pharmaceuticals, these risks are amplified, potentially impacting patient care and national security if supply chains are compromised.

What performance metrics are typically used to evaluate the effectiveness of a pharmaceutical prime vendor contract?

The effectiveness of a pharmaceutical prime vendor contract is typically evaluated through a range of performance metrics. Key indicators often include on-time delivery rates, order fill rates (percentage of requested items successfully supplied), accuracy of shipments, and response times to urgent requests. Additionally, metrics related to inventory management, product quality (ensuring drugs are within expiration dates and properly stored), and adherence to regulatory compliance are crucial. Customer satisfaction surveys from the end-users (e.g., VA medical facilities) can also provide valuable feedback. For fixed-price contracts, monitoring cost performance against the agreed-upon rates and ensuring no unauthorized price escalations occur is also vital. These metrics collectively assess the vendor's reliability, efficiency, and overall contribution to the healthcare mission.

How does the VA's Pharmaceutical Prime Vendor program contribute to the overall healthcare delivery for veterans?

The VA's Pharmaceutical Prime Vendor (PPV) program is fundamental to the efficient and effective healthcare delivery for veterans. By consolidating pharmaceutical procurement through prime vendors like McKesson, the VA streamlines a complex and critical aspect of its operations. This model ensures that a wide range of necessary medications are readily available across the vast network of VA medical centers and clinics nationwide. It reduces the administrative burden associated with managing numerous individual drug contracts, allowing healthcare providers to focus more on patient care. Furthermore, the prime vendor system is designed to leverage economies of scale, potentially leading to cost savings and ensuring a consistent supply chain, which is vital for managing chronic conditions and acute medical needs common among the veteran population.

Industry Classification

NAICS: Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing

Product/Service Code: MEDICAL/DENTAL/VETERINARY EQPT/SUPP

Competition & Pricing

Extent Competed: FULL AND OPEN COMPETITION

Solicitation Procedures: NEGOTIATED PROPOSAL/QUOTE

Pricing Type: FIRM FIXED PRICE (J)

Evaluated Preference: NONE

Contractor Details

Address: 6555 STATE HIGHWAY 161, IRVING, TX, 75039

Business Categories: Category Business, Corporate Entity Not Tax Exempt, Not Designated a Small Business, Special Designations, U.S.-Owned Business

Financial Breakdown

Contract Ceiling: $609,005,032

Exercised Options: $609,005,032

Current Obligation: $609,005,032

Contract Characteristics

Multi-Year Contract: Yes

Commercial Item: COMMERCIAL ITEM

Cost or Pricing Data: NO

Parent Contract

Parent Award PIID: 36W79720D0001

IDV Type: IDC

Timeline